Click here to get full coverage on New Analyst Forecast: $STOK Given $36 Price Target - Quiver Quantitative

New Analyst Forecast: $STOK Given $36 Price Target  Quiver Quantitative

New Analyst Forecast: $STOK Given $36 Price Target - Quiver Quantitative

Click here to get full coverage on Biotech firm to share RNA medicine work at major J.P. Morgan event - Stock Titan

Biotech firm to share RNA medicine work at major J.P. Morgan event  Stock Titan

Biotech firm to share RNA medicine work at major J.P. Morgan event - Stock Titan

Click here to get full coverage on Analyst Raises Price Target for STOK: Stoke Therapeutics | STOK Stock News - GuruFocus

Analyst Raises Price Target for STOK: Stoke Therapeutics | STOK Stock News  GuruFocus

Analyst Raises Price Target for STOK: Stoke Therapeutics | STOK Stock News - GuruFocus

Click here to get full coverage on Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Chardan Capital - MarketBeat

Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Chardan Capital  MarketBeat

Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Chardan Capital - MarketBeat

Click here to get full coverage on Discipline and Rules-Based Execution in STOK Response - Stock Traders Daily

Discipline and Rules-Based Execution in STOK Response  Stock Traders Daily

Discipline and Rules-Based Execution in STOK Response - Stock Traders Daily

Click here to get full coverage on My Favorite Store-Bought Coffee Is Better Than Any Drive-Thru Drink - Allrecipes

My Favorite Store-Bought Coffee Is Better Than Any Drive-Thru Drink  Allrecipes

My Favorite Store-Bought Coffee Is Better Than Any Drive-Thru Drink - Allrecipes

Click here to get full coverage on Stoke Therapeutics (NASDAQ:STOK) shareholders are still up 246% over 3 years despite pulling back 4.8% in the past week - Yahoo Finance

Stoke Therapeutics (NASDAQ:STOK) shareholders are still up 246% over 3 years despite pulling back 4.8% in the past week  Yahoo Finance

Stoke Therapeutics (NASDAQ:STOK) shareholders are still up 246% over 3 years despite pulling back 4.8% in the past week - Yahoo Finance

Click here to get full coverage on We Ranked the Best Bottled Cold Brew Coffee—and Yes, Starbucks Cold Brew Made the List - Sporked

We Ranked the Best Bottled Cold Brew Coffee—and Yes, Starbucks Cold Brew Made the List  Sporked

We Ranked the Best Bottled Cold Brew Coffee—and Yes, Starbucks Cold Brew Made the List - Sporked

Click here to get full coverage on Michael Stok - Waukon Standard Newspaper

Michael Stok  Waukon Standard Newspaper

Michael Stok - Waukon Standard Newspaper

Click here to get full coverage on Stoke Therapeutics (STOK) Valuation After Positive Long-Term Zorevunersen Data at AES Meeting - simplywall.st

Stoke Therapeutics (STOK) Valuation After Positive Long-Term Zorevunersen Data at AES Meeting  simplywall.st

Stoke Therapeutics (STOK) Valuation After Positive Long-Term Zorevunersen Data at AES Meeting - simplywall.st

Click here to get full coverage on CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $36 - 富途牛牛

CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $36  富途牛牛

CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $36 - 富途牛牛

Click here to get full coverage on STOK Crosses Above Average Analyst Target - Nasdaq

STOK Crosses Above Average Analyst Target  Nasdaq

STOK Crosses Above Average Analyst Target - Nasdaq

Click here to get full coverage on Stoke Therapeutics (STOK): New Analyst Price Target Raises to $3 - GuruFocus

Stoke Therapeutics (STOK): New Analyst Price Target Raises to $3  GuruFocus

Stoke Therapeutics (STOK): New Analyst Price Target Raises to $3 - GuruFocus

Click here to get full coverage on Equities Analysts Set Expectations for STOK FY2027 Earnings - MarketBeat

Equities Analysts Set Expectations for STOK FY2027 Earnings  MarketBeat

Equities Analysts Set Expectations for STOK FY2027 Earnings - MarketBeat

Click here to get full coverage on Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates  Yahoo Finance

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance

Click here to get full coverage on I Tried 10 Store-Bought Cold Brew Coffees and This Is the Only One Worth Buying - Allrecipes

I Tried 10 Store-Bought Cold Brew Coffees and This Is the Only One Worth Buying  Allrecipes

I Tried 10 Store-Bought Cold Brew Coffees and This Is the Only One Worth Buying - Allrecipes

Click here to get full coverage on How Investors May Respond To Stoke Therapeutics (STOK) Data Suggesting Disease‑Modifying Potential In Dravet Syndrome - simplywall.st

How Investors May Respond To Stoke Therapeutics (STOK) Data Suggesting Disease‑Modifying Potential In Dravet Syndrome  simplywall.st

How Investors May Respond To Stoke Therapeutics (STOK) Data Suggesting Disease‑Modifying Potential In Dravet Syndrome - simplywall.st

Click here to get full coverage on Stoke Therapeutics Inc (STOK) Q3 2025 Earnings Call Highlights: Strong Financial Position and ... - Yahoo Finance

Stoke Therapeutics Inc (STOK) Q3 2025 Earnings Call Highlights: Strong Financial Position and ...  Yahoo Finance

Stoke Therapeutics Inc (STOK) Q3 2025 Earnings Call Highlights: Strong Financial Position and ... - Yahoo Finance

Click here to get full coverage on A Look at Stoke Therapeutics (STOK) Valuation After a 167% Year-to-Date Surge - Yahoo Finance

A Look at Stoke Therapeutics (STOK) Valuation After a 167% Year-to-Date Surge  Yahoo Finance

A Look at Stoke Therapeutics (STOK) Valuation After a 167% Year-to-Date Surge - Yahoo Finance

Click here to get full coverage on Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains? - Yahoo Finance

Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains?  Yahoo Finance

Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains? - Yahoo Finance

Click here to get full coverage on Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117% - Investor's Business Daily

Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117%  Investor's Business Daily

Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117% - Investor's Business Daily

Click here to get full coverage on Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ... - Yahoo Finance

Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ...  Yahoo Finance

Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ... - Yahoo Finance

Click here to get full coverage on Stoke Therapeutics (STOK): Exploring Valuation After a 2% Monthly Gain and 200% YTD Growth - Yahoo Finance

Stoke Therapeutics (STOK): Exploring Valuation After a 2% Monthly Gain and 200% YTD Growth  Yahoo Finance

Stoke Therapeutics (STOK): Exploring Valuation After a 2% Monthly Gain and 200% YTD Growth - Yahoo Finance

Click here to get full coverage on Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates  Yahoo Finance

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on Leon Stok of IBM Elected Chair of Silicon Integration Initiative Board - Business Wire

Leon Stok of IBM Elected Chair of Silicon Integration Initiative Board  Business Wire

Leon Stok of IBM Elected Chair of Silicon Integration Initiative Board - Business Wire

Click here to get full coverage on (STOK) Movement as an Input in Quant Signal Sets - Stock Traders Daily

(STOK) Movement as an Input in Quant Signal Sets  Stock Traders Daily

(STOK) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Click here to get full coverage on $STOK stock is up 12% today. Here's what we see in our data. - Quiver Quantitative

$STOK stock is up 12% today. Here's what we see in our data.  Quiver Quantitative

$STOK stock is up 12% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Stoke Therapeutics (STOK) Profitability Milestone Tests Bullish Narratives as Earnings Face Declines - simplywall.st

Stoke Therapeutics (STOK) Profitability Milestone Tests Bullish Narratives as Earnings Face Declines  simplywall.st

Stoke Therapeutics (STOK) Profitability Milestone Tests Bullish Narratives as Earnings Face Declines - simplywall.st

Click here to get full coverage on $STOK stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$STOK stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$STOK stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on New Stoke Therapeutics hires receive stock options vesting over 4 years - Stock Titan

New Stoke Therapeutics hires receive stock options vesting over 4 years  Stock Titan

New Stoke Therapeutics hires receive stock options vesting over 4 years - Stock Titan

Click here to get full coverage on Stoke Therapeutics (STOK) Valuation After Positive Long-Term Zorevunersen Data at AES Meeting - Sahm

Stoke Therapeutics (STOK) Valuation After Positive Long-Term Zorevunersen Data at AES Meeting  Sahm

Stoke Therapeutics (STOK) Valuation After Positive Long-Term Zorevunersen Data at AES Meeting - Sahm

Click here to get full coverage on Chobani sued by Danone for allegedly copying cold brew packaging - Food Dive

Chobani sued by Danone for allegedly copying cold brew packaging  Food Dive

Chobani sued by Danone for allegedly copying cold brew packaging - Food Dive

Click here to get full coverage on Stoke Therapeutics (STOK) Unveils Promising Data For Dravet Syndrome Drug - Yahoo Finance

Stoke Therapeutics (STOK) Unveils Promising Data For Dravet Syndrome Drug  Yahoo Finance

Stoke Therapeutics (STOK) Unveils Promising Data For Dravet Syndrome Drug - Yahoo Finance

Click here to get full coverage on Dairy-Free Cold Brew Desserts - Trend Hunter

Dairy-Free Cold Brew Desserts  Trend Hunter

Dairy-Free Cold Brew Desserts - Trend Hunter

Click here to get full coverage on $STOK stock is up 17% today. Here's what we see in our data. - Quiver Quantitative

$STOK stock is up 17% today. Here's what we see in our data.  Quiver Quantitative

$STOK stock is up 17% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on BTIG Reiterates Stoke Therapeutics (STOK) Buy Recommendation - Nasdaq

BTIG Reiterates Stoke Therapeutics (STOK) Buy Recommendation  Nasdaq

BTIG Reiterates Stoke Therapeutics (STOK) Buy Recommendation - Nasdaq

Click here to get full coverage on All You Need to Know About Stoke Therapeutics (STOK) Rating Upgrade to Buy - Yahoo Finance

All You Need to Know About Stoke Therapeutics (STOK) Rating Upgrade to Buy  Yahoo Finance

All You Need to Know About Stoke Therapeutics (STOK) Rating Upgrade to Buy - Yahoo Finance

Click here to get full coverage on How buybacks impact STOK stock value - Market Sentiment Report & Low Entry Investment Ideas - ulpravda.ru

How buybacks impact STOK stock value - Market Sentiment Report & Low Entry Investment Ideas  ulpravda.ru

How buybacks impact STOK stock value - Market Sentiment Report & Low Entry Investment Ideas - ulpravda.ru

Click here to get full coverage on Insider Sale: CHIEF MEDICAL OFFICER of $STOK Sells 1,244 Shares - Quiver Quantitative

Insider Sale: CHIEF MEDICAL OFFICER of $STOK Sells 1,244 Shares  Quiver Quantitative

Insider Sale: CHIEF MEDICAL OFFICER of $STOK Sells 1,244 Shares - Quiver Quantitative

Click here to get full coverage on STOK Beer Debuts in Bengaluru with a Chill-Focused Launch - brewer-world.com

STOK Beer Debuts in Bengaluru with a Chill-Focused Launch  brewer-world.com

STOK Beer Debuts in Bengaluru with a Chill-Focused Launch - brewer-world.com

Click here to get full coverage on Why Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet Syndrome - Yahoo Finance

Why Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet Syndrome  Yahoo Finance

Why Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet Syndrome - Yahoo Finance

Click here to get full coverage on STOKE THERAPEUTICS Earnings Results: $STOK Reports Quarterly Earnings - Quiver Quantitative

STOKE THERAPEUTICS Earnings Results: $STOK Reports Quarterly Earnings  Quiver Quantitative

STOKE THERAPEUTICS Earnings Results: $STOK Reports Quarterly Earnings - Quiver Quantitative

Click here to get full coverage on Allan, general counsel, sells $205k in Stoke Therapeutics (STOK) - Investing.com

Allan, general counsel, sells $205k in Stoke Therapeutics (STOK)  Investing.com

Allan, general counsel, sells $205k in Stoke Therapeutics (STOK) - Investing.com

Click here to get full coverage on Corient Private Wealth LLC Invests $7.49 Million in Stoke Therapeutics, Inc. $STOK - MarketBeat

Corient Private Wealth LLC Invests $7.49 Million in Stoke Therapeutics, Inc. $STOK  MarketBeat

Corient Private Wealth LLC Invests $7.49 Million in Stoke Therapeutics, Inc. $STOK - MarketBeat

Click here to get full coverage on See Channing Tatum Step Up in Stok Cold Brew Super Bowl Ad - ADWEEK

See Channing Tatum Step Up in Stok Cold Brew Super Bowl Ad  ADWEEK

See Channing Tatum Step Up in Stok Cold Brew Super Bowl Ad - ADWEEK

Click here to get full coverage on Kaye Edward M. MD sells Stoke Therapeutics (STOK) stock for $467k - Investing.com

Kaye Edward M. MD sells Stoke Therapeutics (STOK) stock for $467k  Investing.com

Kaye Edward M. MD sells Stoke Therapeutics (STOK) stock for $467k - Investing.com

Click here to get full coverage on Redmile Group LLC Cuts Stock Holdings in Stoke Therapeutics, Inc. $STOK - MarketBeat

Redmile Group LLC Cuts Stock Holdings in Stoke Therapeutics, Inc. $STOK  MarketBeat

Redmile Group LLC Cuts Stock Holdings in Stoke Therapeutics, Inc. $STOK - MarketBeat

Click here to get full coverage on Wrexham to hold stadium promotion party for fans - ESPN

Wrexham to hold stadium promotion party for fans  ESPN

Wrexham to hold stadium promotion party for fans - ESPN

Click here to get full coverage on Kaye Edward M. MD sells Stoke Therapeutics (STOK) shares for $64,541 - Investing.com

Kaye Edward M. MD sells Stoke Therapeutics (STOK) shares for $64,541  Investing.com

Kaye Edward M. MD sells Stoke Therapeutics (STOK) shares for $64,541 - Investing.com

Click here to get full coverage on STOK: HC Wainwright & Co. Raises Price Target to $50 | STOK Stoc - GuruFocus

STOK: HC Wainwright & Co. Raises Price Target to $50 | STOK Stoc  GuruFocus

STOK: HC Wainwright & Co. Raises Price Target to $50 | STOK Stoc - GuruFocus

Click here to get full coverage on Inside the evolution of Danone’s Stōk - Food Dive

Inside the evolution of Danone’s Stōk  Food Dive

Inside the evolution of Danone’s Stōk - Food Dive

Click here to get full coverage on H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK) - Yahoo Finance

H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK)  Yahoo Finance

H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK) - Yahoo Finance

Click here to get full coverage on Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire

Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates  Business Wire

Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire

Click here to get full coverage on Stoke Therapeutics (STOK): JP Morgan Raises Price Target, Mainta - GuruFocus

Stoke Therapeutics (STOK): JP Morgan Raises Price Target, Mainta  GuruFocus

Stoke Therapeutics (STOK): JP Morgan Raises Price Target, Mainta - GuruFocus

Click here to get full coverage on Stoke Therapeutics (NASDAQ:STOK) Director Sells $433,386.10 in Stock - MarketBeat

Stoke Therapeutics (NASDAQ:STOK) Director Sells $433,386.10 in Stock  MarketBeat

Stoke Therapeutics (NASDAQ:STOK) Director Sells $433,386.10 in Stock - MarketBeat

Click here to get full coverage on Noteworthy Friday Option Activity: HLF, STOK, CRCL - Nasdaq

Noteworthy Friday Option Activity: HLF, STOK, CRCL  Nasdaq

Noteworthy Friday Option Activity: HLF, STOK, CRCL - Nasdaq

Click here to get full coverage on Huge update confirmed for Wrexham’s STōK Cae Ras after Leicester match - Leader Live

Huge update confirmed for Wrexham’s STōK Cae Ras after Leicester match  Leader Live

Huge update confirmed for Wrexham’s STōK Cae Ras after Leicester match - Leader Live

Click here to get full coverage on Stoke Therapeutics (NASDAQ:STOK) Shares Up 12.4% - Time to Buy? - MarketBeat

Stoke Therapeutics (NASDAQ:STOK) Shares Up 12.4% - Time to Buy?  MarketBeat

Stoke Therapeutics (NASDAQ:STOK) Shares Up 12.4% - Time to Buy? - MarketBeat

Click here to get full coverage on Allan, general counsel at Stoke, sells $250,650 in STOK stock - Investing.com

Allan, general counsel at Stoke, sells $250,650 in STOK stock  Investing.com

Allan, general counsel at Stoke, sells $250,650 in STOK stock - Investing.com

Click here to get full coverage on My Favorite Store-Bought Coffee Is Better Than Any Drive-Thru Drink - Yahoo

My Favorite Store-Bought Coffee Is Better Than Any Drive-Thru Drink  Yahoo

My Favorite Store-Bought Coffee Is Better Than Any Drive-Thru Drink - Yahoo

Click here to get full coverage on Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - simplywall.st

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?  simplywall.st

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - simplywall.st

Click here to get full coverage on Does Stoke Therapeutics Still Make Sense After Its 2025 Rally And Lofty Valuation Multiples? - simplywall.st

Does Stoke Therapeutics Still Make Sense After Its 2025 Rally And Lofty Valuation Multiples?  simplywall.st

Does Stoke Therapeutics Still Make Sense After Its 2025 Rally And Lofty Valuation Multiples? - simplywall.st

Click here to get full coverage on Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates - Business Wire

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates  Business Wire

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates - Business Wire

Click here to get full coverage on Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - Business Wire

Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference  Business Wire

Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - Business Wire

Click here to get full coverage on Stoke Therapeutics: Vulnerable To Profit Taking (NASDAQ:STOK) - Seeking Alpha

Stoke Therapeutics: Vulnerable To Profit Taking (NASDAQ:STOK)  Seeking Alpha

Stoke Therapeutics: Vulnerable To Profit Taking (NASDAQ:STOK) - Seeking Alpha

Click here to get full coverage on Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Report Preview: What To Expect  Yahoo Finance

Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Click here to get full coverage on Stok Cae Ras: A missing Kop and a San Siro pitch - the changes to Wrexham’s historic home - BBC

Stok Cae Ras: A missing Kop and a San Siro pitch - the changes to Wrexham’s historic home  BBC

STOK

Price Chart

Key Statistics

Technicals

About STOK

Latest News

New Analyst Forecast: $STOK Given $36 Price Target - Quiver Quantitative

Biotech firm to share RNA medicine work at major J.P. Morgan event - Stock Titan

Analyst Raises Price Target for STOK: Stoke Therapeutics | STOK Stock News - GuruFocus

Advanced Charts

Top Gainers

Top Losers